In the subgroup of clinically node-positive breast cancer patients there is a consistent significant difference (p = 0.01) in axillary pCR between subtypes with the highest percentage in HER2-positive breast cancer (83.3%), followed by the TN (46.7%) and ER-positive/HER2-negative subtypes (32.0%). The gene discussed is ESR1; the disease is breast carcinoma.